2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1677

Disease-Regulated Expression of Anti-Inflammatory Interleukin-10 for the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1968

Distinct Distribution Patterns of Large Vessel Vasculitis Assessed with 18f-FDG PET/CT: Evidence from Principal Component and Cluster Analyses

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1160

DNA Hydroxylmethylation Regulates Pro-Inflammatory Cytokine Expression in Macrophages

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1250

DNA Methylation and Its Relation to Immunological Phenotypes in Peripheral Blood: A Study of Anti-CCP Antibody Positivity from a Population-Based Pool

Genetics, Genomics and Proteomics Poster II

9:00AM-11:00AM: Abstract Number: 1610

DNA Methylation Changes Observed in Rheumatoid Arthritis Joint Tissue Are Detectable in CD4+ Naive T Cells from Peripheral Blood

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1620

DNA Methylation Profiling of Rheumatoid Arthritis Peripheral Blood Identifies Hypermethylation of TRIM69 Promoter Region in CD4+ T Cells Associated with Disease Activity

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1974

Do Patients with Giant Cell Arteritis Meet the 2011 United Kingdom Department of Health Guidance on Physical Activity?

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1632

Do RA Susceptibility Loci Predict Response to Methotrexate As First DMARD in Early RA?

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1307

Does Computerized Segmentation of Early Erosions on Magnetic Resonance Imaging Predict Functional Ability in Rheumatoid Arthritis?

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1791

Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients from Atherosclerotic Cardiovascular Events? a Case-Control Study

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1678

Does the Level of Disease Control Achieved with Biologics Influence Overall Costs for Health Care and Work Loss in RA?

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1127

Downregulation of nuclear Factor-Erythroid 2-Related Factor (Nrf2)/Heme Oxygenase-1 Axis in Diabetic Cartilage: Towards a Better Phenotyping of diabetes-Related Osteoarthritis

Biology and Pathology of Bone and Joint Poster I: Osteoarthritis Pathogenesis

9:00AM-11:00AM: Abstract Number: 1987

Dramatic Efficacy of Tocilizumab As First Line Therapy in Patients with Recent Polymyalgia Rheumatica (PMR): Results of the First Longitudinal Prospective Study

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1267

Drug Survival of Second Biologic DMARD Therapy in Patients with Rheumatoid Arthritis: Comparison of a Second Anti-TNF with a Second Non-Anti-TNF after Discontinuation of a First Anti-TNF

Health Services Research Poster II (ACR): Healthcare Access, Patterns of Medication Use and Workforce Considerations

9:00AM-11:00AM: Abstract Number: 1288

Dual Care Utilization in Patients Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry

Health Services Research Poster II (ACR): Healthcare Access, Patterns of Medication Use and Workforce Considerations

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].